In our case, the diagnosis of SMM was supported by the presence of 12% bone marrow plasma cells and a markedly abnormal free light chain ratio, despite an IgA level <30 g/L and no myeloma-defining events. Patients with SMM require careful monitoring for progression to symptomatic multiple myeloma [10]. This evidence concerns the gene CD79A and plasma cell myeloma.